ITMCTR2100005161尚未招募1 期
Clinical Efficacy Evaluation and Mechanism Study of Anti-Hepatic Fibrosis Effectively Treated Prescription by Supplementing Deficiency and Clearing Collaterals
Chengdu University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 性别
- All
入选标准
- •1. Meet the diagnostic criteria for chronic hepatitis B fibrosis;
- •2. Diagnostic criteria of TCM syndrome of Qi deficiency and collateral obstruction;
- •3. Aged between 18-65 years old;
- •4. Good compliance and signed informed consent.
排除标准
- •1. Those with poor compliance;
- •2. Those who are participating in other scientific research projects;
- •3. Diagnosed as severe chronic hepatitis B or prone to severe hepatitis;
- •4. Alcoholic, drug-related, infectious, hereditary, immune, and other viral liver diseases;
- •5. Decompensated patients after hepatitis;
- •6. Patients with severe heart, brain, lung and kidney diseases or tumors;
- •7. Pregnant women or lactating women; mentally ill or unable to cooperate.
研究者
相似试验
尚未招募
1 期
Study for clinical efficacy evaluation and mechanism of Chinese medicine in relieving antibiotic resistance and sensitizing resistant bacteria by taking drug-resistant bacterial diarrhea as an exampleDrug-resistant bacterial diarrhea in childrenITMCTR1900002803Affiliated Hospital of Changchun University of Traditional Chinese Medicine
尚未招募
1 期
Investigating the clinical efficacy and mechanism of Runfei Huayu recipe in treating connective tissue disease merger interstitial lung disease based on Th17/Treg glycolytic pathwayITMCTR2200006523Taizhou Hospital of traditional Chinese Medicine
已完成
不适用
Clinical Research on the efficacy evaluation and the biomarker of nivolumab to an advance malignant melanomamalignant melanomaJPRN-UMIN000016608Public Health Research Foundation128
进行中（未招募）
不适用
A study to investigate belimumab for the treatment of chronic immune thrombocytopeniaChronic Immune ThrombocytopeniaMedDRA version: 15.1Level: LLTClassification code 10051057Term: Idiopathic thrombocytopeniaSystem Organ Class: 100000004851EUCTR2011-000241-21-DEGlaxoSmithKline Research & Development Limited40
进行中（未招募）
不适用
A study to investigate belimumab for the treatment of chronic immune thrombocytopeniaChronic Immune ThrombocytopeniaMedDRA version: 14.1Level: LLTClassification code 10051057Term: Idiopathic thrombocytopeniaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2011-000241-21-GBGlaxoSmithKline Research & Development Limited40